Real-World Status of Augmentation Therapy With Atypical Antipsychotics in Major Depressive Disorder: A Claims Database Study.
- 1Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
- 2Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
- 3Department of Psychiatry, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Abstract
Background
This study investigated pharmacotherapy treatment patterns, focusing on atypical antipsychotics (AAP) augmentation therapy, in patients with major depressive disorder (MDD) who initiated antidepressant monotherapy in Japan.Methods
This retrospective cohort study was conducted using a large Japanese claims database. Patients with MDD aged ≥ 18 years who were subsequently prescribed antidepressants between June 2013 and June 2020 were enrolled. We identified patients who initiated antidepressant monotherapy as the first line of treatment (LOT1). Treatment patterns, including the number, duration, and sequence of LOTs, were examined before and after AAP augmentation therapy.Results
In total, 50 355 patients received antidepressant monotherapy in LOT1; the most common therapy was selective serotonin reuptake inhibitors (SSRIs). The use of AAP augmentation therapy increased with progression of LOTs. Overall, 3811 patients (7.6%) received AAP augmentation therapy after a mean of 1.4 LOTs and 270 days from treatment initiation. Although 37.9% of these patients changed to other treatments in the next LOT within 180 days, 46.4% continued AAP augmentation therapy for ≥ 180 days. Among patients receiving antidepressant monotherapy in LOT1, 14.6% underwent ≥ 3 LOTs and the most common treatment pattern was SSRI-SSRI-SSRI.Conclusions
The proportion of patients receiving AAP augmentation therapy was low. Although few LOTs were required before AAP augmentation therapy, the claims-defined interval before AAP augmentation therapy was relatively long. Approximately half of the patients demonstrated prescription persistence with AAP augmentation therapy for ≥ 180 days. These findings may help clinicians refine treatment strategies regarding the timing of AAP augmentation, providing a basis for future research on how such adjustments might influence therapeutic outcomes in MDD.
Related
- Evaluating the Real-World Safety of Atypical Antipsychotics in Paediatric Autism Spectrum Disorder: Lessons from Saudi Arabia's Pharmacovigilance System.
- Comparative efficacy and safety of quetiapine versus other atypical antipsychotics for behavioral and psychological symptoms in Alzheimer’s disease: a systematic review and meta-analysis
- Pathways to medication adherence: a configurational analysis of psychiatric symptoms and medication attitude in patients with schizophrenia spectrum disorder receiving long-acting injectable antipsychotics.
- Pupil size-resting state network coupling in major depressive disorder: a longitudinal iTBS study
- Biologically informed network-regularized sparse consensus clustering (BioNet-SPACC) identifies a continuous plasma proteomic axis in major depressive disorder
BibTeX
@article{hori2026realworld,
title = {{Real-World Status of Augmentation Therapy With Atypical Antipsychotics in Major Depressive Disorder: A Claims Database Study.}},
author = {Hikaru Hori and Yoshiyuki Shibasaki and Yuki Shiomi and Kazunari Niidome and Takuya Maekawa and Kenji Maeda and Daisuke Sekine and Norihiro Nakamichi and Ken Inada},
journal = {Neuropsychopharmacology reports},
year = {2026},
month = nov,
doi = {10.1002/npr2.70177},
url = {https://europepmc.org/article/MED/42973239},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Real-World Status of Augmentation Therapy With Atypical Antipsychotics in Major Depressive Disorder: A Claims Database Study.
AU - Hikaru Hori
AU - Yoshiyuki Shibasaki
AU - Yuki Shiomi
AU - Kazunari Niidome
AU - Takuya Maekawa
AU - Kenji Maeda
AU - Daisuke Sekine
AU - Norihiro Nakamichi
AU - Ken Inada
PY - 2026
DA - 2026/11/04
JO - Neuropsychopharmacology reports
DO - 10.1002/npr2.70177
UR - https://europepmc.org/article/MED/42973239
AB - Background This study investigated pharmacotherapy treatment patterns, focusing on atypical antipsychotics (AAP) augmentation therapy, in patients with major depressive disorder (MDD) who initiated antidepressant monotherapy in Japan.Methods This retrospective cohort study was conducted using a large Japanese claims database. Patients with MDD aged ≥ 18 years who were subsequently prescribed antidepressants between June 2013 and June 2020 were enrolled. We identified patients who initiated antidepressant monotherapy as the first line of treatment (LOT1). Treatment patterns, including the number, duration, and sequence of LOTs, were examined before and after AAP augmentation therapy.Results In total, 50 355 patients received antidepressant monotherapy in LOT1; the most common therapy was selective serotonin reuptake inhibitors (SSRIs). The use of AAP augmentation therapy increased with progression of LOTs. Overall, 3811 patients (7.6%) received AAP augmentation therapy after a mean of 1.4 LOTs and 270 days from treatment initiation. Although 37.9% of these patients changed to other treatments in the next LOT within 180 days, 46.4% continued AAP augmentation therapy for ≥ 180 days. Among patients receiving antidepressant monotherapy in LOT1, 14.6% underwent ≥ 3 LOTs and the most common treatment pattern was SSRI-SSRI-SSRI.Conclusions The proportion of patients receiving AAP augmentation therapy was low. Although few LOTs were required before AAP augmentation therapy, the claims-defined interval before AAP augmentation therapy was relatively long. Approximately half of the patients demonstrated prescription persistence with AAP augmentation therapy for ≥ 180 days. These findings may help clinicians refine treatment strategies regarding the timing of AAP augmentation, providing a basis for future research on how such adjustments might influence therapeutic outcomes in MDD.
SN - 2574-173X
ER -